| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Aytu BioPharma (NASDAQ:AYTU) is preparing to release its quarterly earnings on Thursday, 2025-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Aytu BioPharma to report an earnings per share (EPS) of $-0.14.
Investors in Aytu BioPharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Last quarter the company missed EPS by $0.21, which was followed by a 17.93% drop in the share price the next day.
Here's a look at Aytu BioPharma's past performance and the resulting price change:
| Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| EPS Estimate | -0.04 | -0.17 | 0.00 | -0.34 |
| EPS Actual | -0.25 | 0.21 | -0.28 | -0.20 |
| Price Change % | -18.00 | 92.00 | -1.00 | -11.00 |
Shares of Aytu BioPharma were trading at $2.1 as of November 11. Over the last 52-week period, shares are up 36.77%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Aytu BioPharma.
The consensus rating for Aytu BioPharma is Buy, based on 2 analyst ratings. With an average one-year price target of $9.75, there's a potential 364.29% upside.
In this analysis, we delve into the analyst ratings and average 1-year price targets of Lipocine and IGC Pharma, three key industry players, offering insights into their relative performance expectations and market positioning.
In the peer analysis summary, key metrics for Lipocine and IGC Pharma are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Aytu BioPharma | Buy | 3.71% | $10.25M | -73.59% |
| Lipocine | Buy | 595.42% | $-1.51M | -12.14% |
| IGC Pharma | Buy | 20.59% | $154K | -25.77% |
Key Takeaway:
Aytu BioPharma ranks at the bottom for Revenue Growth and Gross Profit, while it ranks in the middle for Return on Equity among its peers.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Aytu BioPharma's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 3.71%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -130.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Aytu BioPharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -73.59%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -15.96%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 1.15, Aytu BioPharma faces challenges in effectively managing its debt levels, indicating potential financial strain.
To track all earnings releases for Aytu BioPharma visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AYTU
